Reichman Amir 4

What Happened Amir Reichman, CEO of Scinai Immunotherapeutics Ltd. (SCNI), was granted 400,000,000 restricted share units (RSUs) on June 16, 2026. The award was recorded at $0.00 per share (no cash paid). These RSUs represent contingent rights to ordinary shares that will convert to actual shares upon vesting; each American Depositary Share (ADS) currently represents 4,000 ordinary shares (footnote F1).

Key Details

• Transaction type: Award/Grant (code A) on 2026-06-16; filing dated 2026-06-18 (timely).
• Grant size and price: 400,000,000 RSUs @ $0.00; total grant value shown as $0 in the filing.
• Vesting: The 400,000,000 RSUs vest in three equal annual installments, subject to Reichman’s continued service (footnote F2).
• Holdings noted in filing: Footnotes show additional RSUs — 240,000,000 granted 12/22/2025 (vests in 3 equal annual installments, F4) and 71,637,600 from 1/25/2024 with a stepped vesting schedule (F3). Combined, these footnotes reference at least 711,637,600 ordinary shares represented by RSUs subject to vesting.
• ADS conversion: The 400,000,000 ordinary shares equal 100,000 ADS at the current 4,000:1 ratio.
• No 10b5-1 plan, tax withholding, or immediate sale noted in the filing.

Context This was a time‑based compensation grant (RSUs), not an open‑market purchase or sale. RSUs are contingent — they do not equate to immediate vested shares and typically serve as retention/incentive awards; they may dilute outstanding shares when they vest and are settled. The filing appears timely (filed within two business days), and the grant itself does not directly signal buying or selling intent by the insider.